Aude Desnoyer

Sorbonne Université — France

Medicine · Health Sciences

17h-index1.3kcitations97works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(51), Immunotherapy and Immune Responses(34), CAR-T cell therapy research(19), Pharmaceutical Practices and Patient Outcomes(17), Cancer Genomics and Diagnostics(9)

Publications97 total

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
European Urology·2025
Supplementary Data 1 from High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
2025Open Access
Data from High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
2025Open Access
Supplementary Data 1 from High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
2025Open Access
Physicochemical stability of DELSTRIGO®: A combination of three active substances (tenofovir disoproxi fumarate [TDF], lamivudine [3TC] doravirine [DOR]) in the management of occupational in the management of HIV post‐exposure prophylaxis (PEP)
British Journal of Clinical Pharmacology·2025Open Access
High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
Clinical Cancer Research·2025
Stratégie optimisée de priorisation des patients à risque lors de l’analyse pharmaceutique des prescriptions : étude pilote
Le Pharmacien Clinicien·2024Open Access
How to decrease bone marrow collection volume and risk contaminations via the operating room cell concentration?
Bone Marrow Transplantation·2024
184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study
Immuno-Oncology Technology·2023· 2 citedOpen Access
1909P Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Annals of Oncology·2023Open Access
Figure S3 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Figure S6 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Data from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Figure S8 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Figure S9 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Figure S4 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Table S4 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Figure S6 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Table S5 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
Supplementary Methods from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Nathalie Chaput(23), Marie Naigeon(19), Lydie Cassard(13), Lisa Boselli(13), Édouard Auclin(12), Boris Duchemann(12), Jonathan Grivel(12), Benjamin Besse(12), Roberto Ferrara(11), Laura Mezquita(11), Laurence Albigès(10), Caroline Caramella(10), Jordi Remón(10), Bernard Escudier(9), Lizza Hendriks(9), David Planchard(9), Sabina Sangaletti(8), Marina Chiara Garassino(8), Aurélien Marabelle(8), Cécile Dalban(8)